FDA approves Ipsen’s Dysport to treat upper limb spasticity in children

This article was originally published here

The regulator has expanded the use of Dysport for injection to treat upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral

The post FDA approves Ipsen’s Dysport to treat upper limb spasticity in children appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply